Hospital
Baptist Memorial Hospital Union County, INC.
Baptist Memorial Hospital Union County, INC. was paid $32.79M by Medicaid between Jan 2018 and Dec 2024, across 287 billing codes. Its largest line is 99284, emergency room visit (serious) — 16% of everything it billed.
33Billing provider infoBAPTIST MEMORIAL HOSPITAL UNION COUNTY, INC.
NEW ALBANY, MS 38652
NEW ALBANY, MS 38652
33aNPI1780648352assigned 04/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$32.79M
24GClaims1,054,476
24DCodes billed287
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Mississippi
Rank by total paid#14 of 77
Median peer was paid$8.23M
This provider vs. median4.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DUCKETT, GREGORY controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 118,361 | $3.82M | |
| 2019 | 106,018 | $3.85M | |
| 2020 | 93,977 | $3.01M | |
| 2021 | 195,953 | $5.04M | |
| 2022 | 218,339 | $6.59M | |
| 2023 | 177,900 | $5.73M | |
| 2024incomplete | 143,928 | $4.76M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 16% | 26,616 | 21,099 | $5.26M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 12% | 28,850 | 23,291 | $3.88M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 10% | 16,499 | 12,591 | $3.31M |
| J9271 | Injection, pembrolizumab, 1 mg | 6.8% | 656 | 313 | $2.22M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.8% | 17,373 | 12,577 | $1.25M |
| G0378 | Hospital observation service, per hour | 3.1% | 2,411 | 1,605 | $1.01M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 4,992 | 3,943 | $746K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.3% | 9,257 | 7,857 | $744K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 2.2% | 8,468 | 3,554 | $732K |
| J0897 | Injection, denosumab, 1 mg | 2.0% | 1,513 | 986 | $642K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.9% | 22,271 | 14,769 | $637K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.9% | 11,190 | 3,224 | $629K |
275 more codes
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.9% | 8,972 | $615K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 1.8% | 14,595 | $604K |
| 71045 | Radiologic examination, chest; single view | 1.8% | 17,150 | $596K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.5% | 45,587 | $507K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.4% | 2,554 | $464K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.4% | 10,413 | $457K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 1.4% | 4,974 | $454K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.3% | 15,011 | $439K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.2% | 18,698 | $408K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.2% | 4,473 | $403K |
| J1439 | Injection, ferric carboxymaltose, 1 mg | 1.1% | 1,528 | $353K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 7,013 | $321K |
| 80053 | Comprehensive metabolic panel | <1% | 64,289 | $314K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 6,834 | $311K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 73,937 | $286K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 17,429 | $233K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 14,170 | $219K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 2,385 | $211K |
| 36415 | Collection of venous blood by venipuncture | <1% | 77,856 | $185K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,448 | $174K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 6,087 | $156K |
| J2505 | Injection, pegfilgrastim, 6 mg | <1% | 216 | $151K |
| 86900 | <1% | 2,829 | $140K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 3,375 | $136K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 14,111 | $132K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 20,168 | $124K |
| J1726 | Injection, hydroxyprogesterone caproate, (makena), 10 mg | <1% | 378 | $119K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,929 | $107K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,595 | $97K |
| D0272 | Bitewings - two radiographic images | <1% | 148 | $90K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,363 | $81K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 2,530 | $81K |
| 74018 | <1% | 2,024 | $73K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,317 | $71K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 61 | $68K |
| 87807 | <1% | 6,463 | $68K | |
| 84484 | <1% | 12,644 | $68K | |
| 96416 | <1% | 833 | $65K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 7,662 | $63K |
| 83880 | <1% | 3,403 | $62K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,136 | $62K |
| J9299 | Injection, nivolumab, 1 mg | <1% | 16 | $62K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | <1% | 1,999 | $62K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,682 | $60K |
| 96367 | <1% | 2,695 | $59K | |
| 73562 | <1% | 1,598 | $55K | |
| 73610 | <1% | 1,344 | $52K | |
| 81003 | <1% | 31,543 | $52K | |
| D2930 | Prefabricated stainless steel crown - primary tooth | <1% | 693 | $51K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 614 | $48K |
| 73630 | <1% | 1,309 | $48K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 3,942 | $47K |
| 86850 | <1% | 2,191 | $47K | |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | <1% | 132 | $46K |
| 86901 | <1% | 2,856 | $44K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 333 | $42K |
| 87040 | <1% | 7,467 | $42K | |
| J0185 | Injection, aprepitant, 1 mg | <1% | 840 | $42K |
| 96417 | <1% | 1,710 | $39K | |
| 72131 | <1% | 1,039 | $38K | |
| 81025 | <1% | 7,242 | $37K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 479 | $37K |
| 76770 | <1% | 744 | $36K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,583 | $36K |
| 73030 | <1% | 1,113 | $36K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,695 | $30K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 4,535 | $29K |
| 93971 | <1% | 810 | $29K | |
| 29515 | <1% | 392 | $28K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 171 | $27K |
| 83735 | <1% | 10,254 | $27K | |
| 85027 | <1% | 9,167 | $27K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 75 | $26K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 5,506 | $26K |
| 84702 | <1% | 2,675 | $26K | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 410 | $25K |
| 83690 | <1% | 6,215 | $25K | |
| 86769 | <1% | 1,079 | $22K | |
| J3111 | Injection, romosozumab-aqqg, 1 mg | <1% | 96 | $22K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 3,250 | $22K |
| 82728 | <1% | 5,462 | $22K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 451 | $21K |
| 84703 | <1% | 3,976 | $20K | |
| 71250 | <1% | 714 | $20K | |
| 73130 | <1% | 514 | $20K | |
| 96411 | <1% | 761 | $19K | |
| 87641 | <1% | 989 | $19K | |
| 96415 | <1% | 726 | $18K | |
| 70486 | <1% | 327 | $17K | |
| 86140 | <1% | 9,072 | $17K | |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | <1% | 97 | $16K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 746 | $15K |
| D3220 | Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction | <1% | 339 | $15K |
| 87640 | <1% | 989 | $14K | |
| Q3014 | Telehealth originating site facility fee | <1% | 952 | $14K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 1,006 | $13K |
| 86160 | <1% | 4,978 | $13K | |
| 83550 | <1% | 5,408 | $12K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 170 | $12K |
| 83605 | <1% | 2,697 | $12K | |
| J0640 | Injection, leucovorin calcium, per 50 mg | <1% | 1,181 | $11K |
| D2934 | <1% | 17 | $10K | |
| 83540 | <1% | 5,438 | $9K | |
| 97162 | <1% | 240 | $9K | |
| 73110 | <1% | 248 | $9K | |
| 73502 | <1% | 333 | $9K | |
| 76641 | <1% | 173 | $8K | |
| 85379 | <1% | 1,896 | $8K | |
| 86300 | <1% | 1,369 | $8K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 77 | $8K |
| 82378 | <1% | 1,789 | $7K | |
| 29125 | <1% | 149 | $7K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 115 | $7K |
| 82607 | <1% | 1,846 | $7K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 569 | $7K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 375 | $7K |
| 96402 | <1% | 430 | $6K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,265 | $6K |
| 83615 | <1% | 2,871 | $6K | |
| J9190 | Injection, fluorouracil, 500 mg | <1% | 1,894 | $6K |
| 96523 | <1% | 346 | $6K | |
| 85610 | <1% | 2,785 | $5K | |
| 82570 | <1% | 2,666 | $5K | |
| 94375 | <1% | 74 | $5K | |
| 85652 | <1% | 6,237 | $5K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 13,419 | $4K |
| 85730 | <1% | 1,605 | $4K | |
| 76830 | Ultrasound, transvaginal | <1% | 63 | $4K |
| 76536 | <1% | 63 | $4K | |
| 96377 | <1% | 395 | $4K | |
| 82565 | <1% | 1,489 | $4K | |
| 72100 | <1% | 97 | $4K | |
| 36600 | <1% | 155 | $4K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 18,467 | $4K |
| 82746 | <1% | 1,207 | $4K | |
| 84156 | <1% | 2,845 | $4K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 181 | $4K |
| 83516 | <1% | 1,054 | $4K | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 3,143 | $4K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 181 | $4K |
| 97166 | <1% | 76 | $3K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 6,192 | $3K |
| 86038 | <1% | 780 | $3K | |
| 85007 | <1% | 1,218 | $3K | |
| 82784 | <1% | 1,999 | $3K | |
| 84550 | <1% | 1,731 | $3K | |
| 85045 | <1% | 2,316 | $3K | |
| 84439 | <1% | 935 | $3K | |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 1,046 | $3K |
| 12001 | <1% | 31 | $3K | |
| 92523 | <1% | 12 | $2K | |
| 76801 | <1% | 37 | $2K | |
| 73590 | <1% | 61 | $2K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 29 | $2K |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 12 | $2K |
| 72128 | <1% | 59 | $2K | |
| D1120 | Dental cleaning, child | <1% | 197 | $2K |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 160 | $2K |
| 84165 | <1% | 1,295 | $2K | |
| 82803 | <1% | 146 | $2K | |
| 12002 | <1% | 12 | $2K | |
| 86225 | <1% | 327 | $2K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 54 | $2K |
| 82951 | <1% | 180 | $2K | |
| 85014 | <1% | 1,170 | $2K | |
| 96401 | <1% | 154 | $2K | |
| 87070 | <1% | 271 | $2K | |
| 74019 | <1% | 41 | $1K | |
| D1208 | Topical application of fluoride, excluding varnish | <1% | 227 | $1K |
| 36416 | <1% | 1,939 | $1K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 10,244 | $1K |
| 86235 | <1% | 333 | $1K | |
| 86308 | <1% | 306 | $1K | |
| 82550 | <1% | 539 | $1K | |
| 87210 | <1% | 356 | $1K | |
| 73090 | <1% | 46 | $1K | |
| 85018 | <1% | 723 | $1K | |
| 83883 | <1% | 474 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 169 | $977.18 |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 19 | $935.76 |
| J9045 | Injection, carboplatin, 50 mg | <1% | 220 | $894.86 |
| 72110 | <1% | 13 | $847.48 | |
| 87205 | <1% | 277 | $788.54 | |
| 80074 | <1% | 52 | $778.96 | |
| 74022 | <1% | 14 | $777.72 | |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 1,018 | $757.09 |
| 82731 | <1% | 16 | $729.37 | |
| 86431 | <1% | 438 | $673.81 | |
| 93017 | <1% | 18 | $662.44 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 39 | $656.12 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 4,603 | $633.41 |
| 86480 | <1% | 57 | $615.26 | |
| 82150 | <1% | 137 | $534.75 | |
| 86200 | <1% | 162 | $491.69 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 22 | $484.48 |
| A9270 | Non-covered item or service | <1% | 6,063 | $483.01 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 1,040 | $471.70 |
| 83655 | <1% | 44 | $461.43 | |
| 73080 | <1% | 15 | $440.62 | |
| 86334 | <1% | 163 | $415.41 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,356 | $378.08 |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 764 | $371.03 |
| 83010 | <1% | 93 | $309.50 | |
| 80061 | Lipid panel | <1% | 32 | $258.93 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 2,412 | $241.65 |
| 90686 | <1% | 52 | $230.89 | |
| J7042 | 5% dextrose/normal saline (500 ml = 1 unit) | <1% | 896 | $230.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 774 | $192.11 |
| 87046 | <1% | 21 | $183.21 | |
| 82375 | <1% | 26 | $178.32 | |
| 87427 | <1% | 21 | $176.38 | |
| 0011A | <1% | 14 | $157.26 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,147 | $155.39 |
| 86780 | <1% | 14 | $143.88 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 297 | $143.87 |
| 82952 | <1% | 46 | $137.03 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,778 | $117.79 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 8,895 | $109.90 |
| 87045 | <1% | 12 | $107.34 | |
| 81001 | <1% | 66 | $103.11 | |
| 84132 | <1% | 27 | $94.05 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,182 | $80.58 |
| 82247 | <1% | 36 | $77.92 | |
| 82270 | <1% | 34 | $71.89 | |
| 83521 | <1% | 1,466 | $69.92 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 3,089 | $63.65 |
| 96368 | <1% | 1,351 | $57.62 | |
| 86301 | <1% | 20 | $56.38 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 5,774 | $41.77 |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 939 | $40.78 |
| 82009 | <1% | 12 | $28.61 | |
| 36592 | <1% | 48 | $17.91 | |
| 84100 | <1% | 19 | $17.08 | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,447 | $16.78 |
| 96376 | <1% | 3,670 | $16.58 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 6,503 | $11.10 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 3,896 | $5.09 |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | <1% | 208 | $4.28 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 352 | $2.90 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 1,953 | $2.58 |
| J2360 | Injection, orphenadrine citrate, up to 60 mg | <1% | 535 | $2.16 |
| J0595 | Injection, butorphanol tartrate, 1 mg | <1% | 635 | $2.15 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,773 | $1.51 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,334 | $1.44 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 310 | $0.76 |
| G0008 | Administration of influenza virus vaccine | <1% | 50 | $0.10 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | <1% | 4,029 | $0.02 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 1,004 | $0.00 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | 0% | 36 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 1,279 | $0.00 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 43 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 415 | $0.00 |
| 0352U | 0% | 102 | $0.00 | |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 70 | $0.00 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | 0% | 664 | $0.00 |
| 36591 | 0% | 343 | $0.00 | |
| D0230 | Intraoral - periapical each additional radiographic image | 0% | 144 | $0.00 |
| J1010 | Injection, methylprednisolone acetate, 1 mg | 0% | 61 | $0.00 |
| J2790 | Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) | 0% | 30 | $0.00 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 54 | $0.00 |
| J1940 | Injection, furosemide, up to 20 mg | 0% | 13 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 14 | $0.00 |
| 77063 | Screening digital breast tomosynthesis, bilateral | 0% | 13 | $0.00 |
| J7510 | Prednisolone oral, per 5 mg | 0% | 922 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 46 | $0.00 |
| 90715 | 0% | 265 | $0.00 | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | 0% | 159 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 450 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 57 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 34 | $0.00 |
| D0220 | Intraoral - periapical first radiographic image | 0% | 131 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 42 | $0.00 |
| J3489 | Injection, zoledronic acid, 1 mg | 0% | 12 | $0.00 |
| 84112 | 0% | 18 | $0.00 | |
| J0689 | Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg | 0% | 21 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDUCKETT, GREGORY (SR VP/ CLO)
Parent organizationBAPTIST MEMORIAL HEALTH CARE CORP.
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.